Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Gruber (Rueil Malmaison, France), C. Taillé (Paris, France), P. Chanez (Marseille, France), G. Devouassoux (Lyon, France), A. Didier (Toulouse, France), C. Pison (Grenoble, France), G. Garcia (Paris, France), A. Bourdin (Montpellier, France), C. Pribil (Rueil Malmaison, France), M. Humbert (Paris, France). Real-life experience with mepolizumab in the French early access program for severe eosinophilic asthma. 1654

Member's Comments

No comment yet.

Related content which might interest you: Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme Source: Eur Respir J, 55 (6) 1902345; 10.1183/13993003.02345-2019 Year: 2020 Real-life treatment of severe eosinophilic asthma with mepolizumab Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 The Anglo-French real-life experience of maintenance OCS use in omalizumab-treated patients with severe persistent allergic asthma Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Mepolizumab in real-life treatment of severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Omalizumab decreases medical resource utilisation in patients with severe allergic asthma in an Italian real-life setting Source: International Congress 2017 – Asthma management Year: 2017 Mepolizumab is effective in severe eosinophilic asthmatics: an Austrian real-life study. Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Super-responder analysis and real-world one year effectiveness of benralizumab in severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study) Source: Eur Respir J, 59 (1) 2100396; 10.1183/13993003.00396-2021 Year: 2022 Experience with Mepolizumab in a cohort of patients with eosinophilic severe persistent asthma Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 The use of omalizumab in the management of severe chronic paediatric asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008 Anti-IL5 therapy could prevent lung function decline in severe eosinophilic asthma: data from the belgian severe asthma registry Source: Virtual Congress 2021 – Clinical features and new biomarkers of asthma, COPD and chronic cough Year: 2021 Real-world effectiveness of reslizumab for severe eosinophilic asthma (SEA) Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Follow-up of patients with severe eosinophilic asthma receiving mepolizumab for one year in specialized asthma clinics in Greece. Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma Year: 2020 Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma Year: 2020 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Late Breaking Abstract - The impact of treatment with mepolizumab on airway remodeling in patients with severe eosinophilic asthma. Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Clinical response to mepolizumab in patients with severe eosinophilic asthma Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Patients’ perception of allergic asthma and their compliance to omalizumab in an Italian clinical setting Source: International Congress 2017 – Asthma management Year: 2017 Late Breaking Abstract - Patients with severe eosinophilic asthma benefit from the treatment with Anti-IL-5 Reslizumab – a real life study from Austria Source: International Congress 2018 – Notable Studies in Asthma Year: 2018